LLY
Eli Lilly and CompanyNYSEHealthcare$935.62-1.98%OpenMarket Cap: $883.99B
As of 2026-04-06
Valuation
P/E (TTM)
42.83
PEG
0.45
P/B
31.66
P/S
13.56
EV/EBITDA
32.91
DCF Value
$743.43
FCF Yield
1.0%
Div Yield
0.7%
Margins & Returns
Gross Margin
83.8%
Operating Margin
45.6%
Net Margin
31.7%
ROE
97.9%
ROA
20.6%
ROIC
30.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $19.29B | 85.1% | $8.78B | $6.64B | $7.39 | $1.50 |
| FY 2025 | $65.18B | 83.8% | $29.70B | $20.64B | $22.95 | $6.00 |
| Q3 2025 | $17.60B | 82.9% | $8.39B | $5.58B | $6.21 | $1.50 |
| Q2 2025 | $15.56B | 84.3% | $7.13B | $5.66B | $6.29 | $1.50 |
| Q1 2025 | $12.73B | 82.5% | $5.41B | $2.76B | $3.06 | $1.50 |
| Q4 2024 | $13.53B | 82.2% | $5.80B | $4.41B | $4.88 | $1.30 |
| FY 2024 | $45.04B | 81.3% | $17.50B | $10.59B | $11.71 | $5.20 |
| Q3 2024 | $11.44B | 81.0% | $4.55B | $970.3M | $1.07 | $1.30 |
| Q2 2024 | $11.30B | 80.8% | $4.42B | $2.97B | $3.28 | $1.30 |
| Q1 2024 | $8.77B | 80.9% | $2.74B | $2.24B | $2.48 | $1.30 |
| Q4 2023 | $9.35B | 80.9% | $3.19B | $2.19B | $2.42 | $1.13 |
| FY 2023 | $34.12B | 79.2% | $10.79B | $5.24B | $5.80 | $4.52 |